Clinical trial
TCD Followed by autoSCT for Newly Diagnosed MM Patients
NCT00349115 · Korean Multiple Myeloma Working Party, Other · Unknown status
Key facts
| NCT number | NCT00349115 |
|---|---|
| Title | TCD Followed by autoSCT for Newly Diagnosed MM Patients |
| Official title | Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients |
| Lead sponsor | Korean Multiple Myeloma Working Party, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 43 |
| Start date | Jun 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Jul 6, 2006 |
| Last update posted | May 6, 2008 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: